Jazz Pharmaceuticals posts record quarterly revenue, raises 2026 guidance
The company launched Ziihera in first-line gastric cancer, closed its Actio acquisition, and lifted full-year revenue guidance to $4.775-$4.85 billion.
Jazz Pharmaceuticals reported third quarter 2026 results on November 2, 2026, with quarterly revenues of $1.2 billion, up 10% year over year.1 The company said it raised its 2026 total revenue guidance to a range of $4.775 to $4.85 billion.1
On the pipeline side, Jazz received FDA approval and rapidly launched Ziihera-based combinations in first-line gastroesophageal adenocarcinoma.1 The approval came on August 25, 2026, for the first-line treatment of adult patients with HER2-positive unresectable locally advanced or metastatic GEA.1 At ESMO, the company presented final analysis from the HERIZON-GEA-01 trial showing sustained survival benefit at three years, with Ziihera plus tislelizumab and chemotherapy showing an improved overall survival hazard ratio of 0.65.1 Specifically, nearly 40% of patients were alive at three years with that combination, irrespective of PD-L1 status, achieving a median overall survival of 27 months.1
Jazz also closed its acquisition of Actio Biosciences, Inc., adding ABS-1230 (JZP6979) to its rare epilepsy portfolio.1 The asset is a potential first-in-class precision therapy for KCNT1-related epilepsy, currently being evaluated in the Phase 1b/2a KYRON trial designed as a registrational study to support a U.S. NDA submission1, with the company planning to present initial patient data at a medical meeting in the fourth quarter of 2026.1
For Epidiolex/Epidyolex, the company confirmed a PDUFA target action date of April 16, 2027 for its oral cannabidiol capsule formulation NDA.1 For Modeyso, Jazz said it anticipates the overall survival interim analysis for the Phase 3 ACTION trial in the first half of 2027, based on current event accrual pace.1
On cash position, Jazz reported that as of September 30, 2026, cash, cash equivalents and investments were $2.9 billion, with long-term debt of $5.6 billion1, and generated $1.3 billion of cash from operations for the nine months ended September 30, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.